The oncogenic function of EZH2 may be augmented by the methylation-dependent degradation of tumour suppressive proteins such as RORα in cancer, thus providing an attractive prototype, suggesting the cross-regulation of oncogenes and tumour suppressor genes for efficient tumour progression. The gene discussed is EZH2; the disease is cancer.